The PeBoW Complex: A novel Drug Target and Biomarker (P18208)

Target Name: PeBoW complex

NCBI ID: P18208

PeBoW complex

Other Name(s): None

The PeBoW Complex: A novel Drug Target and Biomarker

Introduction

The PeBoW complex, also known as Pyruvate Kinase (PK), is a protein that plays a crucial role in the metabolism of pyruvate, a critical amino acid found in all living organisms. The ability of this enzyme to catalyze the conversion of pyruvate to acetyl -CoA, a key intermediate in the citric acid cycle, makes it an attractive drug target and a potential biomarker for various diseases. In this article, we will explore the structure, function, and potential therapeutic applications of the PeBoW complex.

Structure and Function

The PeBoW complex is a protein that consists of three subunits: E1 (64 amino acids), E2 (64 amino acids), and E3 (32 amino acids). The subunits are held together by disulfide bonds, and the complex has a characteristic X -Ray structure with a unique fold that allows for efficient substrate binding. E1 and E2 subunits contain a nucleotide-binding domain (NBD), which is responsible for the binding of pyruvate and is crucial for the catalytic activity of the complex ( 2).

The PeBoW complex functions by catalyzing the conversion of pyruvate to acetyl-CoA through a series of intermediate steps. The first step involves a Michaelis-Menten-like rate constant (kcat) reaction, in which the NBD of E1 subunit binds to pyruvate and generates a Michaelis constant (kM) value. The second step is the transfer of the acetyl group from pyruvate to the carbonyl group of E2 subunit, which creates a covalent bond and reduces the NBD to a part. The third step is the final transfer of the acetyl group from pyruvate to the carbonyl group of E3 subunit, which completes the conversion of pyruvate to acetyl-CoA.

The unique feature of the PeBoW complex is its ability to catalyze the conversion of pyruvate to acetyl-CoA in the absence of oxygen. This property is critical for its function in aerobic organisms, where oxygen is limiting for the citric acid cycle. The ability of the PeBoW complex to function in the absence of oxygen makes it an attractive drug target for diseases caused by the overproduction of pyruvate, such as phenylketonuria (PKU).

Potential Therapeutic Applications

The PeBoW complex has the potential to be a drug target for various diseases caused by the overproduction of pyruvate. One of the most promising targets is PKU, a genetic disorder that is caused by a deficiency of phenylalanine hydroxylase (PAH). PKU patients are unable to break down phenylalanine, which leads to an accumulation of phenylalanine and its derivatives in the brain, leading to a wide range of health problems, including developmental delays, mental retardation, and behavioral issues.

The PeBoW complex has been shown to be involved in the metabolism of phenylalanine, which is a byproduct of the phenylalanine hydroxylase (PAH) enzyme. Studies have shown that the PeBoW complex can significantly increase the activity of the PAH enzyme, leading to an increase in the levels of phenylalanine in the brain. This increase in phenylalanine levels is thought to contribute to the symptoms of PKU, including the accumulation of phenylalanine in the brain and the development of PKU-related behavioral issues.

Another therapeutic potential application of the PeBoW complex is its potential as a biomarker for various diseases caused by the overproduction of pyruvate. The ability of the PeBoW complex to catalyze the conversion of pyruvate to acetyl-CoA makes it a useful target for diseases in which the overproduction

Protein Name: PeBoW Complex

The "PeBoW complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PeBoW complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets